Accendra Health Inc. (ACH) is a Medical Specialities company listed on NYSE. In the last 30 days Quantisnow tracked 12 wire items for ACH, including 7 SEC filings, 2 earnings updates and 2 press releases and news items. The most recent was published Nov 5, 2026.
Financial highlights
Full financials- Revenue, TTM
- $2.55B
- Revenue growth
- -7.1%
- Net income, TTM
- -$171.56M
- Net margin
- -6.7%
- Free cash flow, TTM
- -$199.12M
- Cash
- $26.61M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks53+100%
2026-05-172026-11-08
Mix2290d
- SEC Filings11(50%)
- Other5(23%)
- Insider3(14%)
- Earnings2(9%)
- Leadership1(5%)
Activity · 52 weeks7539 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form 10-Q filed by Accendra Health Inc.10-Q - ACCENDRA HEALTH INC/VA/ (0000075252) (Filer)
- SECAccendra Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ACCENDRA HEALTH INC/VA/ (0000075252) (Filer)
- PRAccendra Health Reports Third Quarter 2026 Financial ResultsAccendra Health, Inc. (NYSE:ACH) (the Company) today reported financial results for the third quarter ended September 30, 2026. Unless otherwise noted, the results herein reflect the Company’s continuing operations, which represent what was previously the Patient Direct segment and certain functional operations. "Over the several weeks since I started, a number of themes have become clear to me. We have strong brands, favorable end markets, and a teammate population dedicated to our mission, Bringing Care To Life. It is equally clear to me that our results to date in 2026 have fallen well short of our expectations and potential. We have identified four key areas which are critical to our
- INSIDERSEC Form 3 filed by new insider Lloyd Scott Macrae3 - ACCENDRA HEALTH INC/VA/ (0000075252) (Issuer)
- SECAccendra Health Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - ACCENDRA HEALTH INC/VA/ (0000075252) (Filer)
- SECAccendra Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure8-K - ACCENDRA HEALTH INC/VA/ (0000075252) (Filer)
- PRAccendra Health Announces Extension of $150 Million Receivables Sale Program To 2029Accendra Health, Inc. (NYSE:ACH) (the "Company") today announced that it executed an amendment to its Receivables Purchase Agreement (the "Receivables Sale Program") on October 29, 2026. The amendment, among other things, extends the Scheduled Termination Date of the facility to October 2029, and the $150 million size of the Receivables Sale Program is unchanged. "We are pleased to have worked with our banking partner to extend the Receivables Sale Program until October of 2029. The facility size remains unchanged, further ensuring the Company’s liquidity strength, and we believe that this continued partnership demonstrates the strength of our accounts receivable portfolio and processes,"
- SECAccendra Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits8-K - ACCENDRA HEALTH INC/VA/ (0000075252) (Filer)
- PRAccendra Health Receives Continued Listing Standard Notice from NYSE Regarding Market Capitalization and Stockholders’ Equity; Intends to Submit Business Plan and Return to Compliance with NYSE Listing StandardAccendra Health, Inc. (NYSE:ACH) (the Company) today announced that on October 27, 2026, it received a notice (the "Notice") from the New York Stock Exchange (the "NYSE") notifying the Company that it is not in compliance with Section 802.01B of the NYSE’s continued listing standards that the Company have an average market capitalization of not less than $50.0 million over a consecutive 30 trading-day period and stockholders’ equity of not less than $50.0 million. The Notice does not result in the immediate delisting of the Company’s Class A Common Stock (the "Common Stock") from the NYSE. The Company intends to respond to the NYSE within ten business days of receipt of the Notice affirmi
- SECSEC Form DEF 14A filed by Accendra Health Inc.DEF 14A - ACCENDRA HEALTH INC/VA/ (0000075252) (Filer)
- PRAccendra Health Announces Third Quarter 2026 Earnings Release Date and Conference CallAccendra Health, Inc. (NYSE:ACH) (the "Company") plans to release financial results for the third quarter of 2026 on Thursday, November 5, 2026, after trading ends on the New York Stock Exchange.The Company will host a conference call for investors and analysts at 5:00 p.m. EST on the same day. Participants may access the call via the toll-free dial-in number at 1-833-461-5787, or the toll dial-in number at 1-585-542-9983. The conference ID access code is 829 856 607.All interested stakeholders are encouraged to access the simultaneous live webcast by visiting the Investor Relations page of the Accendra Health website available at investors.accendra.com/events-and-presentations/. A replay of
- SECSEC Form PRE 14A filed by Accendra Health Inc.PRE 14A - ACCENDRA HEALTH INC/VA/ (0000075252) (Filer)
- SECSEC Form 8-K filed by Accendra Health Inc.8-K - ACCENDRA HEALTH INC/VA/ (0000075252) (Filer)
- PRAccendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing StandardAccendra Health, Inc. (NYSE:ACH) (the Company) today announced that on October 6, 2026, it received a notice (the "Notice") from the New York Stock Exchange (the "NYSE") notifying the Company that it is not in compliance with the NYSE’s continued listing standards because the average closing price of the Company’s Class A Common Stock (the "Common Stock") was less than $1.00 per share over a consecutive 30 trading-day period. The Notice does not result in the immediate delisting of the Company’s Common Stock from the NYSE. The Company intends to respond to the NYSE within ten business days of receipt of the Notice affirming its intent to cure the deficiency. Pursuant to the NYSE’s rul
- SECSEC Form SCHEDULE 13G filed by Accendra Health Inc.SCHEDULE 13G - ACCENDRA HEALTH INC/VA/ (0000075252) (Subject)
- INSIDERSEC Form 4 filed by Accendra Health Inc.4 - ACCENDRA HEALTH INC/VA/ (0000075252) (Issuer)
- SECAmendment: Accendra Health Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K/A - ACCENDRA HEALTH INC/VA/ (0000075252) (Filer)
- INSIDEREVP & CFO Leon Jonathan A covered exercise/tax liability with 4,265 shares, decreasing direct ownership by 1% to 286,268 units (SEC Form 4) (for withholding tax)4 - ACCENDRA HEALTH INC/VA/ (0000075252) (Issuer)
- SECAccendra Health Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure8-K - ACCENDRA HEALTH INC/VA/ (0000075252) (Filer)
- PRAccendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company’s Next Chapter of GrowthGardner-Smith to Succeed Ed Pesicka Following Previously Announced Retirement Company Announces Scott Lloyd as Chief Commercial Officer Accendra Health, Inc. (NYSE:ACH) (the "Company") today named Kenneth Gardner-Smith as the Company’s next President and Chief Executive Officer. Gardner-Smith, who has served on the Company’s Board of Directors since March 2022, is expected to assume the role early in the fourth quarter 2026. He will succeed Edward A. Pesicka, who announced his intent to retire in August. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917344754/en/Kenneth Gardner-Smith Gardner-Smith brings deep experience
- SECAccendra Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ACCENDRA HEALTH INC/VA/ (0000075252) (Filer)
- PRAccendra Health Updates on Capital Allocation and CEO Succession Timing PlansAccendra Health (the "Company") is providing an update on its capital allocation plans and the timeline for the replacement of its chief executive officer. Given recent market conditions, the Company has determined that it is in the best interest of stakeholders not to put in place an at-the-market issuance program. The program was intended to allow the Company to opportunistically issue modest amounts of equity over time, with the proceeds to be used to reduce outstanding indebtedness, including debt trading at discounts to par value. The program was never intended as a source of liquidity for the Company. Not implementing the program will have no impact on the Company’s results of opera
- ANALYSTAccendra Health downgraded by Citigroup with a new price targetCitigroup downgraded Accendra Health from Buy to Neutral and set a new price target of $1.50
- ANALYSTAccendra Health downgraded by Robert W. Baird with a new price targetRobert W. Baird downgraded Accendra Health from Outperform to Neutral and set a new price target of $1.50
- SECSEC Form 8-A12B filed by Accendra Health Inc.8-A12B - ACCENDRA HEALTH INC/VA/ (0000075252) (Filer)
ACH FAQ
10 questionsWhat does Accendra Health Inc. do?
Aluminum Corporation of China Limited, together with its subsidiaries, manufactures and sells alumina, primary aluminum, and energy products in the People's Republic of China. The company operates through Alumina, Primary Aluminum, Trading, and Energy segments. The Alumina segment mines for and purchases bauxite and other raw materials; and produces and sells alumina, as well as refined alumina. The Primary Aluminum segment procures alumina and other raw materials, supplemental materials, and electrical power; and produces and sells aluminum and aluminum-related products, such as carbon...What is the latest news on ACH?
In the last 30 days Quantisnow tracked 12 wire items for ACH: 7 SEC filings, 2 earnings updates, 2 press releases and news items and 1 insider trade. The most recent was published on November 5, 2026.What is ACH revenue?
Accendra Health Inc. (ACH) reported $2.55B of revenue for the twelve months ended Sep 30, 2026. That is down 7.1% from the year before. Revenue for fiscal 2025 was $2.76B.Is ACH profitable?
No. Accendra Health Inc. reported a net loss of $171.56M for the twelve months ended Sep 30, 2026.How much cash and debt does ACH have?
Accendra Health Inc. reported $26.61M in cash and cash equivalents and $1.75B of debt on its most recent balance sheet in SEC filings.Where does ACH stock trade?
Accendra Health Inc. (ACH) is listed on NYSE.What sector and industry is ACH in?
Accendra Health Inc. operates in the Health Care sector, Medical Specialities industry.What are analysts saying about ACH?
Across the last 4 analyst actions on Accendra Health Inc., there were 2 upgrades and 2 downgrades. The most recent action was from Robert W. Baird: Neutral with a $1.50 price target on 2026-08-11. Recent price targets cluster around $1.50.What companies are similar to ACH?
Notable peers in the same industry include ELV (Elevance Health Inc.), HUM (Humana Inc.), NTRA (Natera Inc.), CI (The Cigna Group), UNH (UnitedHealth Group Incorporated). Compare ACH side-by-side with any of them on Quantisnow.How can I track ACH on Quantisnow?
Quantisnow aggregates Accendra Health Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ACH to receive live email and push alerts on every new disclosure.